“Korea biosimilars are very successful, but manufacturers still need to work on dependency”
“Korean biosimilar manufacturers must raise dependent capability for them not to rely on foreign partners in a long-term. In order to do so, they must fully understand the global market and have enough investments.”
Murray Aitken, Head of IMS Institute for Health Information, stressed securement...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
